MENU
+Compare
VRDN
Stock ticker: NASDAQ
AS OF
Jul 28, 04:59 PM (EDT)
Price
$17.26
Change
-$0.02 (-0.12%)
Capitalization
1.41B

VRDN Viridian Therapeutics Forecast, Technical & Fundamental Analysis

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease... Show more

Industry: #Biotechnology
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for VRDN with price predictions
Jul 25, 2025

VRDN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for VRDN turned positive on July 07, 2025. Looking at past instances where VRDN's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on VRDN as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VRDN advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 140 cases where VRDN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for VRDN moved out of overbought territory on July 24, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 56 cases where VRDN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRDN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VRDN broke above its upper Bollinger Band on July 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VRDN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRDN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.392) is normal, around the industry mean (18.019). P/E Ratio (0.000) is within average values for comparable stocks, (59.593). VRDN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.512). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. VRDN's P/S Ratio (5000.000) is very high in comparison to the industry average of (279.374).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

VRDN is expected to report earnings to rise 14.94% to -100 cents per share on August 06

Viridian Therapeutics VRDN Stock Earnings Reports
Q2'25
Est.
$-1.00
Q1'25
Beat
by $0.11
Q4'24
Beat
by $0.22
Q3'24
Missed
by $0.09
Q2'24
Missed
by $0.15
The last earnings report on May 06 showed earnings per share of -87 cents, beating the estimate of -98 cents. With 194.18K shares outstanding, the current market capitalization sits at 1.41B.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
221 Crescent Street
Phone
+1 617 272-4600
Employees
94
Web
https://www.viridiantherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSUTX130.080.41
+0.32%
Fidelity Select Utilities
QNTIX38.220.10
+0.26%
Meeder Sector Rotation Institutional
BRIFX16.860.04
+0.24%
Baron Real Estate Income Retail
FFIMX21.860.03
+0.14%
Fidelity Advisor Asset Manager 50% I
TIGAX25.53-0.09
-0.35%
Thornburg International Growth A

VRDN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with DNLI. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
-1.20%
DNLI - VRDN
52%
Loosely correlated
-4.47%
AURA - VRDN
51%
Loosely correlated
+2.41%
DSGN - VRDN
49%
Loosely correlated
-0.50%
BEAM - VRDN
49%
Loosely correlated
+3.68%
OCUL - VRDN
48%
Loosely correlated
+2.43%
More